Deutsche Bank
RVPH

Deutsche Bank’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Deutsche Bank’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$2.88K – 3693
2024
Q3 		$2.88K Buy
+100
New +$2.22K ﹤0.01% 3562

Other funds holding RVPH

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank's RVPH Position: Q4 2024 in Review

Deutsche Bank sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q4 2024, closing a stake of 100 shares — an estimated $2.88K sold.

Deutsche Bank first reported a position in RVPH in Q3 2024 and held it in 1 quarter. The position peaked at $2.88K in Q3 2024. 42 funds tracked by Wall St. Rank hold RVPH as of Q4 2024.

  • Deutsche Bank reported no remaining REVIVA PHARMA HLDGS INC position as of Q4 2024 after selling out during the quarter.
  • Deutsche Bank sold 100 REVIVA PHARMA HLDGS INC shares in Q4 2024, an estimated $2.88K.
  • Deutsche Bank first reported a position in REVIVA PHARMA HLDGS INC in Q3 2024 and held it in 1 quarter.
  • Deutsche Bank's REVIVA PHARMA HLDGS INC position peaked at $2.88K in Q3 2024.
  • 42 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q4 2024.

Based on Deutsche Bank's 13F filing for Q4 2024, filed 14 Feb 2025.